Human Metapneumovirus Vaccine
Creative Biolabs is a world leader in the field of viral vaccine development. By consistently delivering the highest standards of quality, professionalism, and integrity, we want to become the partner of a choice for your requirements. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine co-development services for human metapneumovirus. We guarantee the finest results for our customers all over the world.
Human Metapneumovirus
Human metapneumovirus (hMPV) is a negative-stranded single-stranded RNA virus that belongs to the Paramyxoviridae family,) hMPV and its close family member, respiratory syncytial virus, are two major causes of lower respiratory tract infection in the pediatric population. Shortly after its discovery in 2001, hMPV was quickly recognized as a common cause of lower respiratory tract infections in young children, immunocompromised patients and the elderly. Repeated infections often occur, which indicates a heavy medical burden. Seroprevalence studies have shown that primary infections occur before the age of 5 and are reinfected throughout their lives. hMPV includes two genetic groups, A and B and each group has two sub-gene categories, namely A1 and A2; B1 and B2. The four subgroups of HMPV occur with year-to-year variability, and infection with one subgroup provides some serological cross protection.
Inactivated Vaccines
In general, formalin-inactivated viruses have good stability, are easy to manufacture and are biologically safe. However, vaccination with formalin-inactivated human metapneumovirus (hMPV) in animals was observed leading to increased disease after natural infection, including enhanced lung disease and Th2 response, indicating that formalin Inactivated hMPV may not be a suitable vaccine candidate. Thus, other methods of inactivation are also being studied to develop safe vaccines. It has been proved that inactive RSV of nanoemulsion adjuvants can induce long-lasting RSV-specific humoral responses, reduce mucus production and increase viral clearance without Th2 immune-mediated pathology evidence.
Subunit Vaccines
A subunit vaccine is comprised of full length or partial viral protein that is purified or expressed. The expressed proteins are typically in the form of virus-like particle (VLP), nanoparticle or with an immune-potentiating adjuvant. The most immunogenic protein in paramyxovirus is mainly fusion protein F. Some animal studies using hMPV proteins as subunit vaccine candidates have recently been conducted. By using retroviral core particles as a vector, intraperitoneal injection of hMPV F induces a strong humoral immune response against both homologous and heterologous strains. hMPV proteins for protein-based vaccine development also include hMPV glycoprotein G and P proteins. Immunization with hMPV F-based subunit vaccines is promising, but more experiments are needed to be conducted.
Live Attenuated Vaccines
Non-recombinant live attenuated viruses are produced by natural mutations or deletions in the cell during viral passage, with or without experimental pressure (e.g., chemical mutagenesis or cold passage). Some non-recombinant live attenuated RSV vaccines have been evaluated in clinical trials but have shown some side effects and inadequate attenuation. Recombinant live attenuated viruses are produced from cells transfected with the hMPV cDNA genome. Recently, in experimental human infection assays, a wild-type recombinant hMPV has been approved as a suitable parental virus for the development of live attenuated hMPV vaccine candidates.
Creative Biolabs is a highly proactive, robust and diversified company with a strong, scientifically-proven background of viral vaccine development. We have experts who are able to help you with the vaccine development against human metapneumovirus. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
